Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...
Yahoo Finance

Curium Announces Approval of Generic DTPA - Kit for the Preparation of Technetium Tc 99m Pentetate Injection in the U.S.

ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m ...
Yahoo Finance

Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year

PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for new ...
Medindia

Curium Strengthens Its PET Manufacturing Capacity and Expands European Footprint with the Acquisition of Nucleis

PARIS, April 10, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed the acquisition of Nucleis, a specialist in GMP manufacturing and ...
MarketWatch

Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan

The MarketWatch News Department was not involved in the creation of this content. -- A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic ...
Morningstar

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

The acquisition enhances Curium’s manufacturing capacity of Lutetium-177 (Lu-177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium’s Lu-177 ...
PharmiWeb

Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer

Primary staging of patients with high-risk PCa prior to initial curative therapy To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific ...
Finanznachrichten

Curium: Oxford Set To Benefit From New Technology to Diagnose Disease

Curium will shortly open a new facility to manufacture cutting-edge diagnosis technology for diseases like cancer at the Churchill Hospital site, part of Oxford University Hospitals NHS Foundation ...
Medicine Buffalo

Surprise: At high pressures, curium can form unexpected covalent bonds, study finds

BUFFALO, N.Y. and TALLAHASSEE, Fla. — New research shows that curium — one of the heaviest known elements — can be manipulated to a larger degree than previously thought. An international team ...
manilatimes

Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis

The acquisition of Nucleis will: Enhance Curium's PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of ...
The National Law Review

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, ...
Medicine Buffalo

At high pressures, curium can form unexpected covalent bonds, study finds

New research shows that curium — one of the heaviest known elements — can be manipulated to a larger degree than previously thought. An international team published a study on July 15 in the journal ...